{
    "clinical_study": {
        "@rank": "129519", 
        "arm_group": {
            "arm_group_label": "Herceptin", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This study will define an optimal chemotherapy dose regimen of Myocet in combination with\n      paclitaxel and intravenous Herceptin and will evaluate the efficacy and safety of this dose\n      regimen in patients with metastatic or locally advanced breast cancer and HER2\n      overexpression. The anticipated time on study treatment is 3-12 months."
        }, 
        "brief_title": "A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Metastatic or Locally Advanced Breast Cancer", 
        "completion_date": {
            "#text": "September 2009", 
            "@type": "Actual"
        }, 
        "condition": "Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  women 18-70 years of age;\n\n          -  metastatic or locally advanced breast cancer;\n\n          -  HER2 overexpression;\n\n          -  >= 1 measurable lesion.\n\n        Exclusion Criteria:\n\n          -  prior treatment for advanced breast cancer;\n\n          -  prior treatment with Herceptin;\n\n          -  bone or central nervous system metastasis as the only site of disease;\n\n          -  history of another malignancy (except basal cell skin cancer and cancer in situ of\n             the uterine cervix, and contralateral breast cancer) within 5 years of study."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "69", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 3, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02015676", 
            "org_study_id": "M77035"
        }, 
        "intervention": [
            {
                "arm_group_label": "Herceptin", 
                "description": "Loading does of 4 mg/kg IV, followed by 2 mg/kg iv weekly, until disease progression", 
                "intervention_name": "trastuzumab [Herceptin]", 
                "intervention_type": "Drug", 
                "other_name": "Herceptin"
            }, 
            {
                "arm_group_label": "Herceptin", 
                "description": "IV weekly, until disease progression", 
                "intervention_name": "paclitaxel", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Herceptin", 
                "description": "IV every 3 weeks, 6 cycles", 
                "intervention_name": "Myocet", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Paclitaxel", 
                "Trastuzumab", 
                "Doxorubicin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "December 13, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Madrid", 
                    "country": "Spain", 
                    "zip": "28027"
                }
            }
        }, 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_arms": "1", 
        "official_title": "'A Study of the Effect of First Line Treatment With Paclitaxel and Myocet in Combination With Herceptin on Overall Tumor Response in Patients With Metastatic or Locally Advanced Breast Cancer and HER2 Overexpression.'", 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Spain: Agencia Espa\u00f1ola del Medicamento, Ministerio de Sanidad y Consumo"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2009", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Efficacy: Overall response rate (complete and partial response)", 
                "safety_issue": "No", 
                "time_frame": "approximately 4 months"
            }, 
            {
                "measure": "Phase I: Maximum tolerated dose of Myocet and paclitaxel in combination with Herceptin (dose-limiting toxicities)", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02015676"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Time to treatment failure", 
                "safety_issue": "No", 
                "time_frame": "approximately 8 years"
            }, 
            {
                "measure": "Time to response", 
                "safety_issue": "No", 
                "time_frame": "approximately 8 years"
            }, 
            {
                "measure": "Duration of response", 
                "safety_issue": "No", 
                "time_frame": "approximately 8 years"
            }, 
            {
                "measure": "Time to progression", 
                "safety_issue": "No", 
                "time_frame": "approximately 8 years"
            }, 
            {
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "approximately 8 years"
            }, 
            {
                "measure": "Safety: Effect on cardiac contractility as assesses by 12-lead ECG and echocardiography", 
                "safety_issue": "No", 
                "time_frame": "approximately 8 years"
            }, 
            {
                "measure": "Safety: Incidence of adverse events", 
                "safety_issue": "No", 
                "time_frame": "approximately 8 years"
            }, 
            {
                "measure": "Pharmacokinetics: Maximum plasma concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "Cycles 1 and 2 (6 weeks)"
            }, 
            {
                "measure": "Pharmacokinetics: Area under the concentration-time curves", 
                "safety_issue": "No", 
                "time_frame": "Cycles 1 and 2 (6 weeks)"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2001", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}